Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 905 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Saline Infusion Clear all
Completed Phase 4 Interventional Results available

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

NCT03247738
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Cangrelor, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

NCT02059135
View directory record Official record
Conditions
Preeclampsia
Interventions
Recombinant human antithrombin (ATryn), Normal Saline 0.9%
Biological · Other
Lead sponsor
rEVO Biologics
Industry
Eligibility
16 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 15, 2026, 4:55 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravenous Estrogen in Kidney Transplant Study

NCT03663543
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
Conjugated Estrogen, Normal saline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis

NCT01197417
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Intravenous Magnesium Sulfate, Normal Saline Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Years to 21 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Early Phase 1 Interventional

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

NCT06109948
View directory record Official record
Conditions
Healthy, Late Onset Pompe Disease
Interventions
ABX1100 injection for IV infusion, Placebo injection for IV infusion
Drug
Lead sponsor
Aro Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Orange, California • St Louis, Missouri • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial

NCT00100178
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 15, 2026, 4:55 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO

NCT03823417
View directory record Official record
Conditions
Bleeding
Interventions
Tranexamic Acid, Normal saline
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 15, 2026, 4:55 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 15, 2026, 4:55 PM EDT
Recruiting Phase 4 Interventional

Anti-Inflammatory Challenge in Schizophrenia

NCT05823532
View directory record Official record
Conditions
Schizophrenia
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

NCT00059332
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Magnesium Sulfate, Normal Saline
Drug
Lead sponsor
Jeffrey L. Saver
Other
Eligibility
40 Years to 95 Years
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

NCT02462967
View directory record Official record
Conditions
Hypertension, Portal
Interventions
GR-MD-02, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
46
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Results available

Intravenous Acetaminophen in Craniotomy

NCT01598701
View directory record Official record
Conditions
Postoperative Pain
Interventions
Acetaminophen, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 15, 2026, 4:55 PM EDT
Not listed Phase 2 Interventional

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

NCT00606164
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin for Injection, Placebo
Drug
Lead sponsor
Blanchette Rockefeller Neurosciences Insitute
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2008 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Results available

Continuous Lidocaine Infusion for Management of Perioperative Burn Pain

NCT02059902
View directory record Official record
Conditions
Thermal Burns
Interventions
Lidocaine, Placebo
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 15, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

NCT06455319
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 15, 2026, 4:55 PM EDT
Withdrawn Phase 2 Interventional

MAGIK for Femoral/Tibial Shaft Fractures

NCT05627479
View directory record Official record
Conditions
Femoral Shaft Fracture, Tibial Shaft Fracture
Interventions
GIK solution, Isotonic Normal Saline Solution
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 15, 2026, 4:55 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation

NCT03610282
View directory record Official record
Conditions
Anesthesia
Interventions
IV Methylphenidate, Propofol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

NCT02145182
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 15, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Clazakizumab vs. Placebo - COVID-19 Infection

NCT04494724
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 15, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery

NCT04220489
View directory record Official record
Conditions
Opioid Dependence, Chronic Pain
Interventions
Ketamine, Placebo Comparator
Drug
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Neuroprotection in Acute Ischemic Stroke

NCT03320018
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 15, 2026, 4:55 PM EDT
Not listed Phase 3 Interventional

Preventing Acute Kidney Injury (AKI) in Pediatric Patients

NCT03897335
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

NCT05872958
View directory record Official record
Conditions
COVID-19
Interventions
AZD3152, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

NCT01569451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rituximab, Glatiramer Acetate, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 15, 2026, 4:55 PM EDT